Mon, 04th Jan 2016 08:35
Two months after its admission to AIM, Redx Pharma said its first-half results were in line with expectations thanks to progress on potential MRSA drugs. Losses before tax rose 60.5% to £3.26m due to a decrease in grant funding and operating expenses increased 5% to £5.48m. The drug discovery and d
Read moreRedx shares jumped on the news it has reached the pre-clinical development stage with a new anti-infective compound designed to tackle MRSA, the bacteria that causes potentially lethal infections in humans. The pharmaceutical firm said the progress marked a "significant milestone" for its commercial
Read more